Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04633148 |
|
Recruitment Status :
Recruiting
First Posted : November 18, 2020
Last Update Posted : February 2, 2023
|
Sponsor:
AvenCell Europe GmbH
Collaborator:
PHARMALOG Institut für klinische Forschung GmbH
Information provided by (Responsible Party):
AvenCell Europe GmbH
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2023 |
| Estimated Study Completion Date : | July 2024 |